|
| 37839734 | Phase 2 open-label, multicenter, single-arm study of cemiplimab in patients with locally advanced basal cell carcinoma after hedgehog inhibitor therapy: Extended follow-up. | J Am Acad Dermatol | 2024 |
| 37956890 | Season of radiotherapy and outcomes of head & neck cancer patients in the MACH-NC & MARCH meta-analyses. | Radiother Oncol | 2024 |
| 37949350 | Tumor molecular landscape of Epstein-Barr virus (EBV) related nasopharyngeal carcinoma in EBV-endemic and non-endemic areas: Implications for improving treatment modalities. | Transl Res | 2024 |
| 36928072 | The observational clinical registry (cohort design) of the European Reference Network on Rare Adult Solid Cancers: The protocol for the rare head and neck cancers. | PLoS One | 2023 |
| 38074678 | Multidisciplinary management of pregnancy-associated and early post-partum head and neck cancer patients. | Front Oncol | 2023 |
| 37958430 | Baseline Values of Circulating IL-6 and TGF-β Might Identify Patients with HNSCC Who Do Not Benefit from Nivolumab Treatment. | Cancers (Basel) | 2023 |
| 37795454 | Current management and future challenges in salivary glands cancer. | Front Oncol | 2023 |
| 37894434 | The Role of Carbon Ion Therapy in the Changing Oncology Landscape-A Narrative Review of the Literature and the Decade of Carbon Ion Experience at the Italian National Center for Oncological Hadrontherapy. | Cancers (Basel) | 2023 |
| 37745365 | A clinicogenomic model including GARD predicts outcome for radiation treated patients with HPV+ oropharyngeal squamous cell carcinoma. | medRxiv | 2023 |
| 37781187 | Head and neck cancers survival in Europe, Taiwan, and Japan: results from RARECAREnet Asia based on a privacy-preserving federated infrastructure. | Front Oncol | 2023 |
| 37778228 | Pre-treatment risk factors to predict early cisplatin-related nephrotoxicity in locally advanced head and neck cancer patients treated with chemoradiation: A single Institution experience. | Oral Oncol | 2023 |
| 37497213 | Long-lasting responses with chemotherapy followed by T-cell therapy in recurrent or metastatic EBV-related nasopharyngeal carcinoma. | Front Immunol | 2023 |
| 37567147 | Muscle quality and not quantity as a predictor of survival in head and neck squamous cell carcinoma. | Oral Oncol | 2023 |
| 37531234 | Tumor Microenvironment Modifications Induced by Afatinib in Squamous Cell Carcinoma of the Head and Neck: A Window-of-Opportunity Study (EORTC-90111-24111). | Clin Cancer Res | 2023 |
| 37455307 | MRI-based radiomic prognostic signature for locally advanced oral cavity squamous cell carcinoma: development, testing and comparison with genomic prognostic signatures. | Biomark Res | 2023 |
| 37345017 | Development and External Validation of a PET Radiomic Model for Prognostication of Head and Neck Cancer. | Cancers (Basel) | 2023 |
| 37173925 | The Tumor Microenvironment and the Estrogen Loop in Thyroid Cancer. | Cancers (Basel) | 2023 |
| 36974574 | Immune checkpoint inhibitors and Carbon iON radiotherapy In solid Cancers with stable disease (ICONIC). | Future Oncol | 2023 |
| 37004837 | Prognostic radiomic signature for head and neck cancer: Development and validation on a multi-centric MRI dataset. | Radiother Oncol | 2023 |
| 37164774 | The SINTART 1 study. A phase II non-randomised controlled trial of induction chemotherapy, surgery, photon-, proton-Â and carbon ion-based radiotherapy integration in patients with locally advanced resectable sinonasal tumours. | Eur J Cancer | 2023 |
| 37163806 | The SINTART 2 Study. A phase II non-randomised controlled trial of induction chemotherapy, photon-, proton- and carbon-ion-based radiotherapy integration in patients with locally advanced unresectable sinonasal tumours. | Eur J Cancer | 2023 |
| 36925925 | The association of cemiplimab plus sonidegib for synchronous cutaneous squamous cell carcinoma and basal cell carcinoma of the head and neck: Two case reports. | Front Oncol | 2023 |
| 36475458 | Oligometastatic disease from differentiated thyroid cancer: best treatment schemes. | Curr Opin Oncol | 2023 |
| 36806911 | Tumor Mutational Burden as a Predictor of Survival with Durvalumab and/or Tremelimumab Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. | Clin Cancer Res | 2023 |
| 36798825 | A multicenter randomized trial for quality of life evaluation by non-invasive intelligent tools during post-curative treatment follow-up for head and neck cancer: Clinical study protocol. | Front Oncol | 2023 |
| 36733354 | HER2 status in recurrent/metastatic androgen receptor overexpressing salivary gland carcinoma patients. | Front Oncol | 2023 |
| 32009265 | Relevance of apparent diffusion coefficient features for a radiomics-based prediction of response to induction chemotherapy in sinonasal cancer. | NMR Biomed | 2022 |
| 35732102 | NR4A3 fusion molecular profile change pathological diagnosis? A case report. | Oral Oncol | 2022 |
| 35641218 | Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer: Subgroup Analysis of CheckMate 141. | Oncologist | 2022 |
| 35341663 | Corrigendum to "Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma" [Eur J Canc 157 (2021) 250-258]. | Eur J Cancer | 2022 |
| 36551656 | The Interplay between Age and Viral Status in EBV-Related Nasopharyngeal and HPV-Related Oropharyngeal Carcinoma Patients. | Cancers (Basel) | 2022 |
| 36442320 | Immune-based classification of HPV-associated oropharyngeal cancer with implications for biomarker-driven treatment de-intensification. | EBioMedicine | 2022 |
| 36505842 | Salivary gland cancers in elderly patients: challenges and therapeutic strategies. | Front Oncol | 2022 |
| 36455583 | International recommendations for plasma Epstein-Barr virus DNA measurement in nasopharyngeal carcinoma in resource-constrained settings: lessons from the COVID-19 pandemic. | Lancet Oncol | 2022 |
| 36241485 | Which future for de-intensified treatments in HPV-related oropharyngeal carcinoma? | Semin Oncol | 2022 |
| 35932637 | European Head and Neck Society recommendations for head and neck cancer survivorship care. | Oral Oncol | 2022 |
| 36231138 | An Inflammatory Signature to Predict the Clinical Benefit of First-Line Cetuximab Plus Platinum-Based Chemotherapy in Recurrent/Metastatic Head and Neck Cancer. | Cells | 2022 |
| 36328091 | Exploring the role of neutrophil-to-lymphocyte ratio and blood chemistry in head and neck adenoid cystic carcinomas treated with carbon ion radiotherapy. | Radiother Oncol | 2022 |
| 33849307 | Monitoring patients with head and neck cancer for flu-like symptoms during the COVID-19 pandemic. | Tumori | 2022 |
| 35131451 | 'Rare cancers': not all together in clinical studies! | Ann Oncol | 2022 |
| 35121395 | Biological properties of hypoxia-related gene expression models/signatures on clinical benefit of anti-EGFR treatment in two head and neck cancer window-of-opportunity trials. | Oral Oncol | 2022 |
| 35172587 | Xevinapant or placebo plus chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck: TrilynX phase IIIÂ study design. | Future Oncol | 2022 |
| 35200748 | Refining Tumor Treatment in Sinonasal Cancer Using Delta Radiomics of Multi-Parametric MRI after the First Cycle of Induction Chemotherapy. | J Imaging | 2022 |
| 35083153 | Complete Response to Nivolumab in Recurrent/Metastatic HPV-Positive Head and Neck Squamous Cell Carcinoma Patient After Progressive Multifocal Leukoencephalopathy: A Case Report. | Front Oncol | 2022 |
| 34272632 | Methodological approach for determining the Minimal Important Difference and Minimal Important Change scores for the European Organisation for Research and Treatment of Cancer Head and Neck Cancer Module (EORTC QLQ-HN43) exemplified by the Swallowing scale. | Qual Life Res | 2022 |
| 32407532 | Quality of Life With Pembrolizumab for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: KEYNOTE-040. | J Natl Cancer Inst | 2021 |
| 36046116 | Immunotherapy in head and neck squamous cell carcinoma and rare head and neck malignancies. | Explor Target Antitumor Ther | 2021 |
| 33900808 | Management of Salivary Gland Malignancy: ASCO Guideline. | J Clin Oncol | 2021 |
| 33844854 | Bone fracture as a novel immune-related adverse event with immune checkpoint inhibitors: Case series and large-scale pharmacovigilance analysis. | Int J Cancer | 2021 |
| 33704627 | The hidden curve behind COVID-19 outbreak: the impact of delay in treatment initiation in cancer patients and how to mitigate the additional risk of dying-the head and neck cancer model. | Cancer Causes Control | 2021 |